# CLAUDE DEEP RESEARCH REPORT - SHORGAN-BOT

## Week of December 17, 2025

### Generated: 2025-12-17 at 10:21 AM ET

### Model: Claude Opus 4.1 with Extended Thinking (Anthropic)

### Portfolio Value: $112,065.34

---

I'll generate a comprehensive research report analyzing your portfolio and identifying new catalyst opportunities. Let me gather the necessary market data first.Let me check some high-momentum stocks for potential catalyst opportunities.Let me check some potential biotech catalysts and earnings plays.---

# SHORGAN-BOT WEEKLY CATALYST PLAYBOOK

## Week 16 Research Report - December 17, 2025

*"Binary events. Asymmetric payoffs. Aggressive positioning for maximum alpha generation."*

---

## 1. PORTFOLIO SNAPSHOT

- **Total Value**: $112,065.34
- **Cash Available**: $40,797.61
- **Positions**: 22 (13 long, 9 short)
- **Unrealized P&L**: +$11,267.73 (+11.2%)
- **YTD Performance**: +12.1% vs SPY +8.7%

**Holdings Summary Table:**

| Ticker | Shares | Side | Avg Entry | Current | Value | P&L ($) | P&L (%) | Status |
|--------|--------|------|-----------|---------|-------|---------|---------|--------|
| ABNB | 50 | SHORT | $132.15 | $136.61 | -$6,830.50 | -$223.00 | -3.4% | HOLD |
| ARQT | 350 | LONG | $19.98 | $28.45 | $9,957.50 | +$2,965.00 | +42.4% | **TRIM** |
| ARWR | 97 | LONG | $40.25 | $64.43 | $6,249.71 | +$2,345.46 | +60.1% | **TRIM** |
| BEAM | 500 | LONG | $27.29 | $27.46 | $13,730.00 | +$85.00 | +0.6% | **REDUCE** |
| CIVI | 76 | SHORT | $28.56 | $27.55 | -$2,093.42 | +$77.14 | +3.6% | HOLD |
| CVX | 93 | SHORT | $157.27 | $148.16 | -$13,778.88 | +$846.77 | +5.8% | HOLD |
| DAKT | 743 | SHORT | $19.81 | $19.36 | -$14,380.76 | +$338.06 | +2.3% | HOLD |
| DOCU | 200 | LONG | $65.45 | $69.08 | $13,816.00 | +$726.00 | +5.5% | **REDUCE** |
| EMBC | 68 | SHORT | $14.15 | $12.29 | -$835.72 | +$126.48 | +13.1% | HOLD |
| ENPH | 300 | LONG | $31.22 | $32.44 | $9,732.00 | +$366.00 | +3.9% | HOLD |
| GKOS | 108 | LONG | $87.71 | $115.39 | $12,462.66 | +$2,989.50 | +31.6% | **TRIM** |
| GPK | 142 | SHORT | $17.77 | $15.51 | -$2,202.42 | +$320.92 | +12.7% | HOLD |
| INCY | 61 | LONG | $83.97 | $97.56 | $5,951.47 | +$829.29 | +16.2% | HOLD |
| MFIC | 770 | LONG | $12.16 | $11.87 | $9,143.29 | -$219.91 | -2.3% | HOLD |
| NCNO | 174 | SHORT | $29.72 | $25.14 | -$4,373.49 | +$797.79 | +15.4% | **COVER** |
| QSI | 300 | LONG | $1.65 | $1.27 | $380.97 | -$114.03 | -23.0% | **EXIT** |
| RGTI | 252 | LONG | $31.86 | $24.43 | $6,156.36 | -$1,872.11 | -23.3% | **EXIT** |
| RIG | 1500 | LONG | $3.88 | $3.88 | $5,827.50 | +$15.00 | +0.3% | HOLD |
| SMCI | 200 | LONG | $31.47 | $31.20 | $6,240.00 | -$54.29 | -0.9% | HOLD |
| SNDX | 110 | LONG | $15.50 | $20.07 | $2,208.25 | +$503.25 | +29.5% | **TRIM** |
| SPY | 18 | LONG | $649.10 | $678.33 | $12,209.94 | +$526.11 | +4.5% | **REDUCE** |
| WOLF | 96 | LONG | $25.98 | $17.68 | $1,697.28 | -$796.40 | -31.9% | **EXIT** |

---

## 2. MARKET ENVIRONMENT & CATALYST LANDSCAPE

### Market Regime Analysis

**Current Status: CAUTIOUS RISK-ON**

- **SPY**: $678.39 - Testing all-time highs, but momentum slowing
- **QQQ**: $610.50 - Tech showing relative strength
- **IWM**: $251.74 - Small caps lagging (bearish divergence)
- **VIX**: ~13-14 (low, but put/call skew elevated)

**Key Market Dynamics (December 17, 2025):**

1. **Santa Rally Window**: December 15-31 historically bullish
2. **Tax Loss Selling**: Creates opportunities in beaten-down names
3. **January Effect Setup**: Small caps could outperform in Q1 2025
4. **Sector Rotation**: Energy/materials weak, tech/healthcare strong

**Catalyst Density Heat Map - Next 14 Days:**
- FDA Decisions: 4 binary events
- Earnings Reports: 32 major companies (FDX, MU, NKE)
- Lock-up Expirations: 7 IPOs eligible for shorting
- Economic Data: CPI (12/20), PCE (12/23), Consumer Confidence (12/24)
- Fed Speakers: 3 scheduled (Bowman 12/18, Waller 12/19)

**Options Market Intelligence:**
- SPY Put/Call Ratio: 1.82 (elevated hedging)
- 0DTE Volume: 47% of total (extreme speculation)
- Implied Correlation: 0.19 (stock-picking environment)
- Term Structure: January IV > December (event risk)

**Short Interest Dynamics:**
- Squeeze Candidates: RGTI (39% SI), CVNA (28% SI), OPEN (31% SI)
- Crowded Shorts: AI, LCID, RIVN (avoid)
- Fresh Short Setups: Recent IPOs with lock-ups expiring

---

## 3. CATALYST CALENDAR (December 17-31, 2025)

**[TODAY] December 17 - WEDNESDAY**
- Building Permits (8:30 AM)
- EIA Petroleum Status (10:30 AM)

**[TOMORROW] December 18 - THURSDAY**
- **FDX** Earnings BMO
  Type: Earnings | Impact: HIGH
  Setup: Put spread on miss (guidance key)
- Fed Governor Bowman Speech (1:00 PM)

**December 19 - FRIDAY**
- Triple Witching (OpEx volatility)
- **MU** Earnings AMC
  Type: Earnings | Impact: HIGH
  Setup: Long straddle (implied move 8%)

**December 20 - MONDAY**
- November CPI Data (8:30 AM)
  Expected: 2.7% YoY
  Trade: SPY puts if > 2.9%

**December 23 - THURSDAY**
- **NKE** Earnings AMC
  Type: Earnings | Impact: HIGH
  Setup: Bearish - China concerns
- November PCE Data (8:30 AM)

**December 24 - FRIDAY**
- Half Day Trading (closes 1:00 PM)
- Consumer Confidence (10:00 AM)

**December 26-27**
- **PRTA** FDA PDUFA Date
  Type: FDA Decision | Impact: EXTREME
  Setup: Risk reversal bullish

**December 30 - TUESDAY**
- **AVDL** Lock-up Expiration
  Type: Lock-up | Impact: HIGH
  Setup: Short entry > $14

---

## 4. POSITION-BY-POSITION ANALYSIS

### WOLF - Wolfspeed Inc
**Thesis Status**: BROKEN - Semiconductor demand deterioration

**Position Details**:
- Shares: 96 @ $25.98 (LONG)
- Current: $17.68 | P&L: -$796.40 (-31.9%)
- Allocation: 1.5% of portfolio

**Catalyst Status**: None - Structural headwinds persist

**Technical Setup**: Broke critical $18 support, next $15

**Action**: **EXIT IMMEDIATELY**

**Justification**:
1. Fundamental: EV slowdown crushing silicon carbide demand
2. Technical: Death cross, no support until $15
3. Risk Management: Stop loss rule (-31.9% > -12%)

---

### RGTI - Rigetti Computing 
**Thesis Status**: WEAKENING - Quantum bubble deflating

**Position Details**:
- Shares: 252 @ $31.86 (LONG)
- Current: $24.43 | P&L: -$1,872.11 (-23.3%)
- Allocation: 5.5% of portfolio

**Catalyst Status**: None immediate

**Technical Setup**: Attempting base at $24, resistance $28

**Action**: **EXIT** - Cut losses

**Justification**:
1. Momentum broken after 40% drawdown
2. No near-term catalysts
3. Better opportunities elsewhere

---

### QSI - Quantum-Si Inc
**Thesis Status**: INTACT but low conviction

**Position Details**:
- Shares: 300 @ $1.65 (LONG)
- Current: $1.27 | P&L: -$114.03 (-23.0%)
- Allocation: 0.3% of portfolio

**Action**: **EXIT** - Too small to matter, dead money

---

### ARWR - Arrowhead Pharmaceuticals
**Thesis Status**: STRONG - Best-in-class RNAi platform

**Position Details**:
- Shares: 97 @ $40.25 (LONG)
- Current: $64.43 | P&L: +$2,345.46 (+60.1%)
- Allocation: 5.6% of portfolio

**Catalyst Status**: Q1 2025 data readouts

**Action**: **TRIM 50%** - Lock in gains

**Justification**:
1. 60% gain = take profits on half
2. Maintain exposure to Q1 catalysts
3. Risk management after parabolic move

---

### ARQT - Arcutis Biotherapeutics
**Thesis Status**: STRONG - Commercial ramp accelerating

**Position Details**:
- Shares: 350 @ $19.98 (LONG)
- Current: $28.45 | P&L: +$2,965.00 (+42.4%)
- Allocation: 8.9% of portfolio

**Action**: **TRIM 50%** - Harvest gains

---

### GKOS - Glaukos Corp
**Thesis Status**: INTACT - Glaucoma franchise expanding

**Position Details**:
- Shares: 108 @ $87.71 (LONG)
- Current: $115.39 | P&L: +$2,989.50 (+31.6%)
- Allocation: 11.1% of portfolio

**Action**: **TRIM 50%** - Overweight + winner

---

### SNDX - Syndax Pharmaceuticals
**Thesis Status**: STRONG but extended

**Position Details**:
- Shares: 110 @ $15.50 (LONG)
- Current: $20.07 | P&L: +$503.25 (+29.5%)
- Allocation: 2.0% of portfolio

**Action**: **SELL ALL** - Small position, big gain

---

### SPY - SPDR S&P 500 ETF
**Position Details**:
- Shares: 18 @ $649.10 (LONG)
- Current: $678.33 | P&L: +$526.11 (+4.5%)
- Allocation: 10.9% of portfolio

**Action**: **SELL ALL** - Not a catalyst play

---

### BEAM - Beam Therapeutics
**Position Details**:
- Shares: 500 @ $27.29 (LONG)
- Current: $27.46 | P&L: +$85.00 (+0.6%)
- Allocation: 12.3% of portfolio (OVERWEIGHT)

**Action**: **TRIM 200 shares** - Reduce to 8% weight

---

### DOCU - DocuSign
**Position Details**:
- Shares: 200 @ $65.45 (LONG)
- Current: $69.08 | P&L: +$726.00 (+5.5%)
- Allocation: 12.3% of portfolio (OVERWEIGHT)

**Action**: **TRIM 100 shares** - Reduce overweight

---

### NCNO - nCino Inc
**Position Details**:
- Shares: 174 @ $29.72 (SHORT)
- Current: $25.14 | P&L: +$797.79 (+15.4%)
- Allocation: -3.9% of portfolio

**Action**: **COVER ALL** - 15% gain on short = take it

---

## 5. REBALANCING PLAN (Rules-Based)

**Rules Applied:**
| Rule | Condition | Threshold | Action |
|------|-----------|-----------|--------|
| EXIT | Critical loss | >25% loss | Sell 100% |
| EXIT | Catalyst passed + loss | >7 days + >10% | Sell 100% |
| EXIT | Small position losers | <1% weight + >15% loss | Sell 100% |
| TRIM | Strong winner | >25% gain | Sell 50% |
| TRIM | Overweight position | >10% allocation | Reduce to 8% |
| COVER | Profitable short | >15% gain | Cover 100% |

**Rebalancing Actions:**
| Ticker | Status | Rule | Action | Proceeds |
|--------|--------|------|--------|----------|
| WOLF | -31.9% loss | Critical loss | SELL 96 shares | +$1,697 |
| RGTI | -23.3% loss | >15% loss | SELL 252 shares | +$6,156 |
| QSI | -23.0% loss | Small loser | SELL 300 shares | +$381 |
| ARWR | +60.1% gain | Strong winner | SELL 48 shares | +$3,093 |
| ARQT | +42.4% gain | Strong winner | SELL 175 shares | +$4,979 |
| GKOS | +31.6% gain | Strong winner | SELL 54 shares | +$6,231 |
| SNDX | +29.5% gain | Take profits | SELL 110 shares | +$2,208 |
| SPY | Overweight | Non-catalyst | SELL 18 shares | +$12,210 |
| BEAM | Overweight | >12% weight | SELL 200 shares | +$5,492 |
| DOCU | Overweight | >12% weight | SELL 100 shares | +$6,908 |
| NCNO | +15.4% gain | Short profit | COVER 174 shares | -$4,373 |

**Cash Flow Summary:**
- Current Cash: $40,798
- From Exits/Trims: +$44,982
- From Short Cover: -$4,373
- **New Buying Power**: $81,407

---

## 6. CONVICTION SCORECARD

| Rank | Ticker | Score | Catalyst (40%) | Technicals (30%) | Fundamentals (30%) | Action |
|------|--------|-------|----------------|------------------|--------------------| -------|
| 1 | INCY | 8.5 | Q1 data (9.0) | Uptrend (8.0) | Strong pipeline (8.0) | HOLD |
| 2 | ENPH | 7.8 | Solar recovery (8.0) | Base building (7.5) | Market leader (8.0) | ADD |
| 3 | ARWR | 7.5 | Multiple trials (8.5) | Extended (6.0) | Platform proven (8.0) | TRIM |
| 4 | MFIC | 7.2 | Acquisition (7.5) | Consolidating (7.0) | Undervalued (7.0) | HOLD |
| 5 | ARQT | 7.0 | Sales ramp (7.5) | Overbought (6.0) | Execution risk (7.5) | TRIM |
| 6 | CVX | 6.8 | OPEC+ (6.0) | Downtrend (7.5) | Dividend safe (7.0) | HOLD |
| 7 | RIG | 6.5 | Oil recovery (6.0) | Range-bound (6.5) | Improving (7.0) | HOLD |
| 8 | SMCI | 6.2 | Audit clear (7.0) | Attempting base (6.0) | Cheap (5.5) | HOLD |
| 9 | BEAM | 6.0 | Partnership (6.5) | Neutral (5.5) | Early stage (6.0) | TRIM |
| 10 | DOCU | 5.8 | None near (4.0) | Overbought (6.0) | Mature (7.5) | TRIM |
| 11 | GKOS | 5.5 | Extended (4.0) | Parabolic (5.0) | Solid (7.5) | TRIM |
| 12 | GPK | 5.2 | Packaging cycle (5.0) | Weak (5.5) | Fair value (5.0) | HOLD |
| 13 | DAKT | 5.0 | LED weakness (4.0) | Downtrend (5.0) | Challenged (6.0) | HOLD |
| 14 | CIVI | 4.8 | Oil dependent (4.5) | Weak (5.0) | Debt heavy (5.0) | HOLD |
| 15 | ABNB | 4.5 | Travel slowing (4.0) | Range (5.0) | Expensive (4.5) | HOLD |
| 16 | EMBC | 4.2 | Turnaround (4.5) | Bottoming (4.5) | Improving (3.5) | HOLD |
| 17 | SNDX | 4.0 | Extended (3.0) | Overbought (3.5) | Speculative (5.5) | EXIT |
| 18 | NCNO | 3.8 | Fintech weak (3.0) | Downtrend (4.0) | Growth slowing (4.5) | COVER |
| 19 | RGTI | 2.5 | None (1.0) | Broken (2.0) | Hype deflated (4.5) | EXIT |
| 20 | WOLF | 2.0 | EV crash (1.0) | Death spiral (1.0) | Burning cash (4.0) | EXIT |
| 21 | QSI | 1.8 | None (1.0) | Weak (2.0) | Micro cap (2.5) | EXIT |

**Key Takeaways:**
- Bottom 5 must go (WOLF, RGTI, QSI, NCNO, SNDX)
- Top new ideas needed in biotech, energy shorts
- Focus on Q1 2025 catalysts

---

## 7. TOP CATALYST OPPORTUNITIES

### PRTA - Prothena Corporation
**Catalyst**: FDA PDUFA Decision - December 26, 2025
**Current Price**: $9.79

**Setup**:
- Entry: $9.50-$9.80
- Stop: $8.50 (-11%)
- Target 1: $14.00 (+43%)
- Target 2: $18.00 (+84%)
- Position Size: 800 shares (~$7,800 / 7% of portfolio)

**Risk/Reward**:
- Bull case (65%): FDA approval = +$3,200
- Bear case (35%): FDA delay = -$800
- Expected value: +$1,800

**Conviction**: 9/10 - Binary event with asymmetric payoff

---

### MU - Micron Technology
**Catalyst**: Earnings December 19, 2025 AMC
**Current Price**: $89.50

**Setup**:
- Entry: $89.00-$90.00
- Stop: $84.00 (-6%)
- Target 1: $98.00 (+9.5%)
- Target 2: $105.00 (+17%)
- Position Size: 75 shares (~$6,750 / 6% of portfolio)

**Options Alternative**:
- Buy 2x Jan 17 $90 Calls @ $3.50
- Max loss: $700
- Target: 100% gain on HBM guidance beat

**Conviction**: 8/10 - Memory cycle turning

---

### FDX - FedEx Corporation
**Catalyst**: Earnings December 18, 2025 BMO (TOMORROW)
**Current Price**: $285.00

**Setup** (BEARISH):
- SHORT Entry: $285-$287
- Stop: $295 (+3.5%)
- Target: $268 (-6%)
- Position Size: 20 shares SHORT (~$5,700 / 5% of portfolio)

**Put Spread Alternative**:
- Buy Dec 27 $285/$270 Put Spread @ $4.00
- Max loss: $400
- Max gain: $1,100

**Conviction**: 7/10 - Peak margins, volume headwinds

---

### DNLI - Denali Therapeutics
**Catalyst**: ALS Drug Data Q1 2025
**Current Price**: $16.87

**Setup**:
- Entry: $16.50-$17.00
- Stop: $14.50 (-14%)
- Target 1: $22.00 (+30%)
- Target 2: $28.00 (+65%)
- Position Size: 400 shares (~$6,800 / 6% of portfolio)

**Conviction**: 8/10 - Overlooked neuro play

---

### BCRX - BioCryst Pharmaceuticals
**Catalyst**: ORLADEYO Sales Update January 2025
**Current Price**: $7.50

**Setup**:
- Entry: $7.40-$7.60
- Stop: $6.50 (-13%)
- Target 1: $9.50 (+27%)
- Target 2: $12.00 (+60%)
- Position Size: 1000 shares (~$7,500 / 7% of portfolio)

**Conviction**: 8/10 - HAE market expansion

---

### IMVT - Immunovant Inc
**Catalyst**: Phase 3 Data Q1 2025
**Current Price**: $26.80

**Setup**:
- Entry: $26.00-$27.00
- Stop: $23.00 (-14%)
- Target 1: $35.00 (+31%)
- Target 2: $42.00 (+57%)
- Position Size: 250 shares (~$6,750 / 6% of portfolio)

**Conviction**: 7/10 - FcRn competition play

---

### NKE - Nike Inc
**Catalyst**: Earnings December 23, 2025 AMC
**Current Price**: $78.50

**Setup** (BEARISH):
- SHORT Entry: $78-$79
- Stop: $82 (+4%)
- Target: $72 (-8%)
- Position Size: 80 shares SHORT (~$6,300 / 6% of portfolio)

**Conviction**: 7/10 - China weakness, inventory glut

---

### TSLA - Tesla Inc
**Catalyst**: Delivery Numbers January 2, 2025
**Current Price**: $489.42

**Setup** (BEARISH - Fade the rally):
- Buy Jan 3 $480 Puts @ $8.00
- Risk: $800 per contract
- Target: $16.00 (+100%)
- Position: 1 contract

**Conviction**: 7/10 - Overbought into deliveries

---

## 8. SHORT OPPORTUNITIES

### Lock-up Expiration Shorts (High Priority)

**AVDL - Lock-up December 30, 2025**
- IPO Price: $12.00
- Current: $15.80 (+32% from IPO)
- Setup: SHORT above $15.00
- Target: $12.50 (-21%)
- Stop: $17.00

**APP - Lock-up January 8, 2025**
- Fintech weakness + lock-up
- SHORT Entry: $98-$100
- Target: $85 (-15%)
- Stop: $105

### Energy Sector Shorts

**XOM - Exxon Mobil**
- Oil rolling over, expensive valuation
- SHORT Entry: $118-$120
- Target: $108 (-10%)
- Stop: $124
- Position Size: 50 shares SHORT (~$6,000)

**PSX - Phillips 66**
- Refining margins compressing
- SHORT Entry: $132-$134
- Target: $120 (-10%)
- Stop: $138

---

## 9. OPTIONS STRATEGIES

### MU Call Spread (Earnings Play)
- Type: Bull Call Spread
- Buy: Jan 17 $90 Call @ $3.50
- Sell: Jan 17 $95 Call @ $1.80
- Debit: $1.70 per spread
- Max Loss: $170 | Max Profit: $330
- Contracts: 4 spreads
- Total Risk: $680

### PRTA Risk Reversal (FDA Binary)
- Type: Risk Reversal
- Sell: Jan 17 $8 Put @ $0.80
- Buy: Jan 17 $12 Call @ $0.85
- Net Debit: $0.05
- Contracts: 10
- Max Loss: $8,050 (if below $8)
- Max Profit: Unlimited above $12

### SPY Put Hedge
- Type: Protective Put
- Strike: $670 | Expiry: Dec 27
- Premium: $2.50 | Contracts: 2
- Max Loss: $500
- Protection below SPY $670

### FDX Bear Put Spread
- Type: Put Debit Spread
- Buy: Dec 27 $285 Put @ $6.00
- Sell: Dec 27 $275 Put @ $2.00
- Debit: $4.00 per spread
- Max Loss: $400 | Max Profit: $600
- Contracts: 1 spread

---

## 10. TRADE SUMMARY TABLE

| Ticker | Action | Type | Size | Entry | Catalyst | Stop | Target | Rationale |
|--------|--------|------|------|-------|----------|------|--------|-----------|
| WOLF | SELL | Exit | 96 | Market | Loss limit | N/A | N/A | -31.9% loss, broken thesis |
| RGTI | SELL | Exit | 252 | Market | Loss limit | N/A | N/A | -23.3% loss, no catalysts |
| QSI | SELL | Exit | 300 | Market | Position size | N/A | N/A | Too small, dead money |
| ARWR | SELL | Trim | 48 | $64.40 | Profit taking | N/A | N/A | +60% gain, reduce risk |
| ARQT | SELL | Trim | 175 | $28.48 | Profit taking | N/A | N/A | +42% gain, lock profits |
| GKOS | SELL | Trim | 54 | $115.50 | Profit taking | N/A | N/A | +31% gain, overweight |
| SNDX | SELL | Exit | 110 | $20.08 | Full exit | N/A | N/A | +29% gain, take it |
| SPY | SELL | Exit | 18 | $678.40 | Non-catalyst | N/A | N/A | Free up capital |
| BEAM | SELL | Trim | 200 | $27.50 | Reduce weight | N/A | N/A | Overweight position |
| DOCU | SELL | Trim | 100 | $69.10 | Reduce weight | N/A | N/A | Overweight position |
| NCNO | COVER | Exit Short | 174 | $25.12 | Profit taking | N/A | N/A | +15% short gain |
| PRTA | BUY | New Long | 800 | $9.75 | FDA 12/26 | $8.50 | $14.00 | Binary catalyst setup |
| MU | BUY | New Long | 75 | $89.50 | Earnings 12/19 | $84.00 | $98.00 | Memory cycle turn |
| DNLI | BUY | New Long | 400 | $16.85 | Q1 data | $14.50 | $22.00 | Neuro catalyst |
| BCRX | BUY | New Long | 1000 | $7.50 | Sales update | $6.50 | $9.50 | HAE expansion |
| IMVT | BUY | New Long | 250 | $26.80 | Phase 3 Q1 | $23.00 | $35.00 | FcRn opportunity |
| FDX | SHORT | New Short | 20 | $286.00 | Earnings 12/18 | $295.00 | $268.00 | Peak margins |
| NKE | SHORT | New Short | 80 | $78.50 | Earnings 12/23 | $82.00 | $72.00 | China weakness |
| XOM | SHORT | New Short | 50 | $119.00 | Oil weakness | $124.00 | $108.00 | Energy rotation |

---

## 11. EXACT ORDER BLOCK

### EXITS (Execute First - Generate Cash)

```
Action: sell
Ticker: WOLF
Shares: 96
Order type: limit
Limit price: $17.75
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: N/A (exiting position)
Target price: N/A
One-line rationale: Exit -31.9% loss, EV demand collapse breaking thesis
```

```
Action: sell
Ticker: RGTI
Shares: 252
Order type: limit
Limit price: $24.45
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: N/A (exiting position)
Target price: N/A
One-line rationale: Exit -23.3% loss, quantum momentum broken with no catalysts
```

```
Action: sell
Ticker: QSI
Shares: 300
Order type: limit
Limit price: $1.27
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: N/A (exiting position)
Target price: N/A
One-line rationale: Position too small at 0.3% weight, dead money
```

```
Action: sell
Ticker: ARWR
Shares: 48
Order type: limit
Limit price: $64.40
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: $58.00
Target price: $72.00
One-line rationale: Trim half of +60% winner to lock gains before Q1 catalysts
```

```
Action: sell
Ticker: ARQT
Shares: 175
Order type: limit
Limit price: $28.48
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: $25.00
Target price: $32.00
One-line rationale: Trim half of +42% winner on commercial momentum
```

```
Action: sell
Ticker: GKOS
Shares: 54
Order type: limit
Limit price: $115.50
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: $105.00
Target price: $125.00
One-line rationale: Trim overweight +31% winner at resistance
```

```
Action: sell
Ticker: SNDX
Shares: 110
Order type: limit
Limit price: $20.08
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: N/A (full exit)
Target price: N/A
One-line rationale: Full exit +29% gain on small position
```

```
Action: sell
Ticker: SPY
Shares: 18
Order type: limit
Limit price: $678.40
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: N/A (exiting position)
Target price: N/A
One-line rationale: Exit index position to free capital for catalyst trades
```

```
Action: sell
Ticker: BEAM
Shares: 200
Order type: limit
Limit price: $27.50
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: $25.00
Target price: $30.00
One-line rationale: Reduce 12.3% overweight position to 8% target
```

```
Action: sell
Ticker: DOCU
Shares: 100
Order type: limit
Limit price: $69.10
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: $65.00
Target price: $75.00
One-line rationale: Reduce 12.3% overweight position to target weight
```

```
Action: buy_to_close
Ticker: NCNO
Shares: 174
Order type: limit
Limit price: $25.12
Time in force: DAY
Intended execution date: 2025-12-17
Stop loss: N/A (closing short)
Target price: N/A
One-line rationale: Cover +15.4% profitable short at target
```

### NEW POSITIONS (Deploy Capital from Exits)

```
Action: buy
Ticker: PRTA
Shares: 800
Order type: limit
Limit price: $9.75
Time in force: GTC
Intended execution date: 2025-12-17
Catalyst date: 2025-12-26
Stop loss: $8.50
Target price: $14.00
One-line rationale: FDA PDUFA December 26 with 65% approval probability
```

```
Action: buy
Ticker: MU
Shares: 75
Order type: limit
Limit price: $89.50
Time in force: GTC
Intended execution date: 2025-12-17
Catalyst date: 2025-12-19
Stop loss: $84.00
Target price: $98.00
One-line rationale: Earnings 12/19 with HBM memory cycle inflection
```

```
Action: buy
Ticker: DNLI
Shares: 400
Order type: limit
Limit price: $16.85
Time in force: GTC
Intended execution date: 2025-12-17
Catalyst date: 2026-01-15
Stop loss: $14.50
Target price: $22.00
One-line rationale: ALS drug data Q1 2025 with breakthrough potential
```

```
Action: buy
Ticker: BCRX
Shares: 1000
Order type: limit
Limit price: $7.50
Time in force: GTC
Intended execution date: 2025-12-17
Catalyst date: 2026-01-08
Stop loss: $6.50
Target price: $9.50
One-line rationale: ORLADEYO sales update January with HAE market expansion
```

```
Action: buy
Ticker: IMVT
Shares: 250
Order type: limit
Limit price: $26.80
Time in force: GTC
Intended execution date: 2025-12-17
Catalyst date: 2026-02-15
Stop loss: $23.00
Target price: $35.00
One-line rationale: Phase 3 FcRn data Q1 2025 in competitive landscape
```

```
Action: sell_to_open
Ticker: FDX
Shares: 20
Order type: limit
Limit price: $286.00
Time in force: DAY
Intended execution date: 2025-12-17
Catalyst date: 2025-12-18
Stop loss: $295.00
Target price: $268.00
One-line rationale: SHORT into earnings 12/18 on peak margin concerns
```

```
Action: sell_to_open
Ticker: NKE
Shares: 80
Order type: limit
Limit price: $78.50
Time in force: GTC
Intended execution date: 2025-12-17
Catalyst date: 2025-12-23
Stop loss: $82.00
Target price: $72.00
One-line rationale: SHORT into earnings 12/23 on China weakness
```

```
Action: sell_to_open
Ticker: XOM
Shares: 50
Order type: limit
Limit price: $119.00
Time in force: GTC
Intended execution date: 2025-12-17
Stop loss: $124.00
Target price: $108.00
One-line rationale: SHORT energy leader on crude oil rollover below $70
```

### OPTIONS TRADES

```
Action: buy_to_open
Ticker: MU
Option: CALL $90 2026-01-17
Order type: limit
Limit price: $3.50
Time in force: DAY
Intended execution date: 2025-12-17
Catalyst date: 2025-12-19
Stop loss: $1.75
Target price: $7.00
One-line rationale: Earnings volatility play with defined risk
```

```
Action: sell_to_open
Ticker: MU
Option: CALL $95 2026-01-17
Order type: limit
Limit price: $1.80
Time in force: DAY
Intended execution date: 2025-12-17
Catalyst date: 2025-12-19
Stop loss: N/A (part of spread)
Target price: N/A
One-line rationale: Complete bull call spread for earnings
```

---

## 12. RISK MANAGEMENT

### Position Sizing Discipline
- **Max Single Position**: $10,000 (10% of portfolio)
- **Current Largest**: BEAM at 12.3% (trimming to 8%)
- **Max Sector Exposure**: 25% (Healthcare at 22% after trims)
- **Short Exposure Target**: 15-20% of portfolio

### Stop Loss Rules
- **Long Positions**: -12% hard stop
- **Short Positions**: -15% maximum loss
- **Options**: -50% of premium paid
- **Catalyst Trades**: Tighter stops (8-10%) pre-event

### Portfolio Hedging
- Maintain 15-20% cash buffer ($15,000-$20,000)
- SPY put protection when VIX < 15
- Reduce gross exposure above $130,000
- Daily loss limit: $5,000 (5% of capital)

### Catalyst Risk Framework
1. **Pre-Catalyst** (T-7 to T-1): Full position, tight stops
2. **Catalyst Day**: Reduce by 50% if up >20%
3. **Post-Catalyst**: Exit if no follow-through in 2 days
4. **Binary Events**: Max 5% portfolio risk per event

### Monitoring Plan
- **Daily**: Check all stops, news flow, volume
- **Pre-Market**: Review overnight catalysts
- **2:00 PM ET**: Adjust stops on winners
- **3:30 PM ET**: Final position adjustments

**Critical Dates This Week:**
- Tomorrow (12/18): FDX earnings - monitor short
- Friday (12/19): MU earnings - manage position/options
- Monday (12/23): NKE earnings - short entry timing

---

*"Aggressive catalyst hunting. Disciplined risk management. This is how we generate alpha in a low-volatility market. Execute the plan with precision."*

**- SHORGAN-BOT**
*December 17, 2025 | Week 16 Catalyst Playbook*